Sobi Highlights P-III (CORE & CORE2) Trials Results of Olezarsen for Severe Hypertriglyceridemia (sHTG) at EAS 2026

Why It Matters

The results position olezarsen as a potentially first‑in‑class therapy for patients at high risk of pancreatitis, addressing an unmet need in lipid management and opening a sizable market opportunity.

Key Takeaways

• Olezarsen 80 mg reduced triglycerides 66% in six months
• 50 mg dose achieved 59% triglyceride reduction
• 85% of patients reached TG < 10 mmol/L threshold
• EMA validated indication; FDA granted priority review for sHTG

Pulse Analysis

The CORE and CORE2 trials mark a pivotal moment for antisense therapeutics targeting lipid disorders. By delivering up to a two‑thirds reduction in triglyceride levels, olezarsen demonstrates efficacy that rivals or exceeds existing fibrates and omega‑3 formulations, especially in patients with TG ≥ 880 mg/dL who face a heightened risk of acute pancreatitis. This efficacy, coupled with favorable effects on remnant cholesterol and non‑HDL‑C, suggests a broader cardiometabolic benefit that could reshape treatment algorithms for severe hypertriglyceridemia.

Regulatory momentum underscores the commercial promise of olezarsen. The European Medicines Agency’s validation of an indication extension signals confidence in the drug’s risk‑benefit profile, while the U.S. Food and Drug Administration’s priority review accelerates the path to market. With a PDUFA date set for June 30, 2026, investors and competitors are closely watching the outcome, as approval could unlock a multi‑billion‑dollar market segment that currently relies on off‑label use of older agents.

Beyond immediate sales potential, olezarsen’s success may catalyze further innovation in RNA‑based lipid therapies. The drug’s mechanism—targeting apolipoprotein C‑III to enhance triglyceride clearance—offers a template for next‑generation molecules aimed at other dyslipidemias. Payers will likely evaluate cost‑effectiveness against existing standards, but the clinical data suggest a compelling case for premium pricing, especially for patients with refractory TG levels and a history of pancreatitis.